180 related articles for article (PubMed ID: 32545904)
1. Cotargeting of XPO1 Enhances the Antileukemic Activity of Midostaurin and Gilteritinib in Acute Myeloid Leukemia.
Brinton LT; Sher S; Williams K; Canfield D; Orwick S; Wasmuth R; Cempre C; Skinner J; Lehman A; Blachly JS; Byrd JC; Lapalombella R
Cancers (Basel); 2020 Jun; 12(6):. PubMed ID: 32545904
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of Bcl-2 Synergistically Enhances the Antileukemic Activity of Midostaurin and Gilteritinib in Preclinical Models of FLT3-Mutated Acute Myeloid Leukemia.
Ma J; Zhao S; Qiao X; Knight T; Edwards H; Polin L; Kushner J; Dzinic SH; White K; Wang G; Zhao L; Lin H; Wang Y; Taub JW; Ge Y
Clin Cancer Res; 2019 Nov; 25(22):6815-6826. PubMed ID: 31320594
[TBL] [Abstract][Full Text] [Related]
3. Gilteritinib: a novel FLT3 inhibitor for acute myeloid leukemia.
Zhao J; Song Y; Liu D
Biomark Res; 2019; 7():19. PubMed ID: 31528345
[TBL] [Abstract][Full Text] [Related]
4. Quizartinib, a selective FLT3 inhibitor, maintains antileukemic activity in preclinical models of RAS-mediated midostaurin-resistant acute myeloid leukemia cells.
Aikawa T; Togashi N; Iwanaga K; Okada H; Nishiya Y; Inoue S; Levis MJ; Isoyama T
Oncotarget; 2020 Mar; 11(11):943-955. PubMed ID: 32215183
[No Abstract] [Full Text] [Related]
5. The Multi-Kinase Inhibitor EC-70124 Is a Promising Candidate for the Treatment of FLT3-ITD-Positive Acute Myeloid Leukemia.
Lopez-Millan B; Costales P; Gutiérrez-Agüera F; Díaz de la Guardia R; Roca-Ho H; Vinyoles M; Rubio-Gayarre A; Safi R; Castaño J; Romecín PA; Ramírez-Orellana M; Anguita E; Jeremias I; Zamora L; Rodríguez-Manzaneque JC; Bueno C; Morís F; Menendez P
Cancers (Basel); 2022 Mar; 14(6):. PubMed ID: 35326743
[TBL] [Abstract][Full Text] [Related]
6. Megakaryocytic Expansion in Gilteritinib-Treated Acute Myeloid Leukemia Patients Is Associated With AXL Inhibition.
Suknuntha K; Choi YJ; Jung HS; Majumder A; Shah S; Slukvin I; Ranheim EA
Front Oncol; 2020; 10():585151. PubMed ID: 33363015
[TBL] [Abstract][Full Text] [Related]
7. Effect of Fms-like tyrosine kinase 3 (FLT3) ligand (FL) on antitumor activity of gilteritinib, a FLT3 inhibitor, in mice xenografted with FL-overexpressing cells.
Kawase T; Nakazawa T; Eguchi T; Tsuzuki H; Ueno Y; Amano Y; Suzuki T; Mori M; Yoshida T
Oncotarget; 2019 Oct; 10(58):6111-6123. PubMed ID: 31692922
[TBL] [Abstract][Full Text] [Related]
8.
Kennedy VE; Smith CC
Front Oncol; 2020; 10():612880. PubMed ID: 33425766
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of gilteritinib in combination with chemotherapy in preclinical models of
Ueno Y; Mori M; Kamiyama Y; Saito R; Kaneko N; Isshiki E; Kuromitsu S; Takeuchi M
Oncotarget; 2019 Apr; 10(26):2530-2545. PubMed ID: 31069015
[TBL] [Abstract][Full Text] [Related]
10. Midostaurin/PKC412 for the treatment of newly diagnosed FLT3 mutation-positive acute myeloid leukemia.
Luskin MR; DeAngelo DJ
Expert Rev Hematol; 2017 Dec; 10(12):1033-1045. PubMed ID: 29069942
[TBL] [Abstract][Full Text] [Related]
11. [Gilteritinib for pediatric FLT3 internal tandem duplication-positive recurrent acute myeloid leukemia].
Fukuoka K; Tsumura Y; Noguchi J; Sugawa M; Takaki T; Hiraki T; Inoue K; Mitani Y; Tomita O; Oshima K; Yanagi M; Isobe K; Mori M; Arakawa Y; Koh K
Rinsho Ketsueki; 2020; 61(4):322-326. PubMed ID: 32378574
[TBL] [Abstract][Full Text] [Related]
12. Midostaurin: an emerging treatment for acute myeloid leukemia patients.
Gallogly MM; Lazarus HM
J Blood Med; 2016; 7():73-83. PubMed ID: 27186148
[TBL] [Abstract][Full Text] [Related]
13. LAM-003, a new drug for treatment of tyrosine kinase inhibitor-resistant FLT3-ITD-positive AML.
Beeharry N; Landrette S; Gayle S; Hernandez M; Grotzke JE; Young PR; Beckett P; Zhang X; Carter BZ; Andreeff M; Halene S; Xu T; Rothberg J; Lichenstein H
Blood Adv; 2019 Nov; 3(22):3661-3673. PubMed ID: 31751472
[TBL] [Abstract][Full Text] [Related]
14. Midostaurin reduces Regulatory T cells markers in Acute Myeloid Leukemia.
Gutierrez L; Jang M; Zhang T; Akhtari M; Alachkar H
Sci Rep; 2018 Dec; 8(1):17544. PubMed ID: 30510164
[TBL] [Abstract][Full Text] [Related]
15. Gilteritinib for the treatment of relapsed and/or refractory FLT3-mutated acute myeloid leukemia.
McMahon CM; Perl AE
Expert Rev Clin Pharmacol; 2019 Sep; 12(9):841-849. PubMed ID: 31454267
[No Abstract] [Full Text] [Related]
16. Heat shock protein 90 inhibitors overcome the resistance to Fms-like tyrosine kinase 3 inhibitors in acute myeloid leukemia.
Katayama K; Noguchi K; Sugimoto Y
Oncotarget; 2018 Sep; 9(76):34240-34258. PubMed ID: 30344940
[TBL] [Abstract][Full Text] [Related]
17. MDM2- and FLT3-inhibitors in the treatment of
Seipel K; Marques MAT; Sidler C; Mueller BU; Pabst T
Haematologica; 2018 Nov; 103(11):1862-1872. PubMed ID: 29976747
[TBL] [Abstract][Full Text] [Related]
18. Incorporating FLT3 inhibitors in the frontline treatment of FLT3 mutant acute myeloid leukemia.
Wang ES
Best Pract Res Clin Haematol; 2019 Jun; 32(2):154-162. PubMed ID: 31203997
[TBL] [Abstract][Full Text] [Related]
19. Midostaurin: a novel therapeutic agent for patients with FLT3-mutated acute myeloid leukemia and systemic mastocytosis.
Gallogly MM; Lazarus HM; Cooper BW
Ther Adv Hematol; 2017 Sep; 8(9):245-261. PubMed ID: 29051803
[TBL] [Abstract][Full Text] [Related]
20. Mechanisms Underlying Resistance to FLT3 Inhibitors in Acute Myeloid Leukemia.
Eguchi M; Minami Y; Kuzume A; Chi S
Biomedicines; 2020 Jul; 8(8):. PubMed ID: 32722298
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
